562824-27-5

Basic information

• Product Name: Di-μ -chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κ N)phenyl- κ C]
• Synonyms: Di-μ -chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κ N)phenyl- κ C];Tetrakis(4,6-difluoro-2-(2-pyridyl)phenyl-C2,N)(μ-dichloro) diiridium(III);C]diiridium, 98%;-chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κ
• CAS NO: 562824-27-5
• Molecular Formula: C44H24Cl2Ir2N4F8
• Molecular Weight: 1216.02
• Mol File: 562824-27-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Di-μ -chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κ N)phenyl- κ C](CAS DataBase Reference)
• NIST Chemistry Reference: Di-μ -chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κ N)phenyl- κ C](562824-27-5)
• EPA Substance Registry System: Di-μ -chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κ N)phenyl- κ C](562824-27-5)

Safety Data

• Hazardous Substances Data: 562824-27-5(Hazardous Substances Data)

Usage

Uses

Used in Coordination Chemistry:
Di-μ-chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κN)phenyl-κC] is utilized as a ligand in coordination chemistry for its ability to form stable complexes with metal ions. This property is crucial for the development of new coordination compounds with tailored properties.
Used in Metal-Organic Frameworks (MOFs):
In the construction of metal-organic frameworks, Di-μ-chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κN)phenyl-κC] serves as a building block. Its incorporation into MOFs can lead to materials with specific porosities, surface areas, and chemical functionalities, which are desirable for various applications such as gas storage, catalysis, and drug delivery.
Used in Catalysis:
Di-μ-chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κN)phenyl-κC] is employed as a catalyst or a catalyst precursor in various chemical reactions. Its unique structure allows it to facilitate transformations that are otherwise difficult to achieve, enhancing the efficiency and selectivity of catalytic processes.
Used in Material Science:
Di-μ -chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κ N)phenylκ C] is used in material science for the development of new materials with specific properties. Its integration into the design of materials can lead to advancements in areas such as electronics, photonics, and energy storage.
Used in Pharmaceutical Industry:
Di-μ-chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κN)phenyl-κC] is used as a potential active pharmaceutical ingredient or a building block in drug design. Its unique coordination capabilities and chemical properties may contribute to the development of new drugs with improved efficacy and selectivity.
The ongoing research into the properties and applications of Di-μ-chlorotetrakis[3,5-difluoro-2-(2-pyridinyl-κN)phenyl-κC] promises to expand its use in these and potentially other fields, as new discoveries are made.

Upstream product

• 1008-89-5 2-phenylpyridine 
• 391604-55-0 2-(2,4-difluorophenyl)pyridine 

Relevant articles and documents

Highly efficient blue and deep-blue emitting zwitterionic iridium(iii) complexes: Synthesis, photophysics and electroluminescence

We report on a series of blue and deep-blue emitting zwitterionic iridium(iii) complexes, consisting formally of a cationic Ir centre and a N,N′-heteroaromatic (N^N) ligand bearing negatively charged side groups, i.e. sulfonate and borate. The synthesis, photophysical and electrochemical properties of this series are described in detail together with their X-ray crystal structure determination. The reported complexes exhibit intense blue (λmax at 450 nm) and deep blue (λmax at 435 nm) emission in deaerated solution, similar to the related cationic complexes. The strategy employed, namely the internal salt formation, allows high solubility in many organic solvents as well as for some of the complexes a low sublimation temperature. For this reason, one of the complexes was further tested as an emitter in phosphorescent organic light emitting diodes (PhOLEDs). Despite the zwitterionic nature of the triplet emitter employed, the devices were fabricated by means of sublimation process. The devices showed a peak external quantum efficiency (EQE) as high as 11.0% and Commission Internationale d'Enclairage (CIE) coordinates x = 0.21 and y = 0.33.

Cyclometalated Ir(iii) complexes as targeted theranostic anticancer therapeutics: Combining HDAC inhibition with photodynamic therapy

The successful design and anticancer mechanistic studies of a series of cyclometalated Ir(iii) complexes with histone deacetylase inhibitory and photodynamic therapy (PDT) activities are reported. This journal is the Partner Organisations 2014.

Synthesis and luminescence properties of iridium complexes chelated with coumarin ligands

According to a recent report, the organic light-emitting diodes (OLEDs) using the iridium complexes of coumarin derivatives as emissive dopants are highly efficient and stable. Unlike the other Ir(III) phopsphorescent dopants, these coumarin-based Ir(III)